(Sharecast News) - Medical imaging and analytics specialist Ixico has been awarded a new contract by an existing client, it announced on Wednesday, to provide imaging services for the extension study of their phase 2b trial for Huntington's disease (HD).
The AIM-traded firm said the contract, valued at just under £2 million, was expected to be executed over the course of the next four years.
"We are delighted to be awarded this contract to support the ongoing development programme of this promising treatment in HD," said chief executive officer Giulio Cerroni.
"This contract strengthens our order book, securing further visibility to future anticipated revenues.
"We have been working with this client for several years and I am delighted to be further deepening our long-term partnership as they pursue a treatment for this terrible neurological disease."
At 1241 BST, shares in Ixico were up 0.03% at 18.25p.
Reporting by Josh White for Sharecast.com.
Ixico (IXI)